Teachers Retirement System of The State of Kentucky boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 27.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,208 shares of the company’s stock after buying an additional 1,750 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Krystal Biotech were worth $2,730,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. purchased a new stake in Krystal Biotech in the 2nd quarter worth about $1,554,113,000. William Blair Investment Management LLC acquired a new stake in Krystal Biotech in the second quarter valued at approximately $211,909,000. Jupiter Topco LLC acquired a new stake in shares of Krystal Biotech in the 2nd quarter valued at $95,387,000. Bank of America Corp DE acquired a new stake in shares of Krystal Biotech in the second quarter worth about $95,308,000. Finally, First Trust Advisors LP lifted its holdings in Krystal Biotech by 42.9% in the 1st quarter. First Trust Advisors LP now owns 350,521 shares of the company’s stock worth $90,547,000 after purchasing an additional 105,245 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.
Krystal Biotech Stock Up 0.2%
KRYS stock opened at $315.82 on Friday. Krystal Biotech, Inc. has a twelve month low of $203.17 and a twelve month high of $382.54. The company has a market cap of $9.36 billion, a P/E ratio of 42.85 and a beta of 0.56. The business’s fifty day moving average is $323.25 and its 200-day moving average is $310.27.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.26. Krystal Biotech had a net margin of 47.91% and a return on equity of 17.02%. The company had revenue of $127.34 million for the quarter, compared to analysts’ expectations of $125.77 million. Research analysts anticipate that Krystal Biotech, Inc. will post 7.74 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
KRYS has been the subject of a number of recent analyst reports. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. HC Wainwright restated a “buy” rating and issued a $361.00 price objective on shares of Krystal Biotech in a research note on Thursday, October 15th. Bank of America raised their target price on Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Royal Bank Of Canada reduced their price target on shares of Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 3rd. Finally, Citigroup decreased their target price on Krystal Biotech from $416.00 to $412.00 and set a “buy” rating on the stock in a report on Tuesday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $375.00.
Get Our Latest Analysis on KRYS
Insider Activity
In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by corporate insiders.
About Krystal Biotech
Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.
See Also
- Five stocks we like better than Krystal Biotech
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
